The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Sun., Oct. 4, 5:14 PM

Slide #3. Medgenics, Inc. Secondary Offering

Company: Medgenics, Inc. (AMEX:MDGN)
Date announced: 9/30/2015
Shares Offered: 6,155,000
Date of Pricing: 10/1/2015
Price Per Share: $6.50
Secondary Offering Details: Medgenics, Inc. (NYSE MKT:MDGN) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. As part of this proposed offering, Medgenics intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered to the public. - updated 10/1 - Medgenics, Inc. (NYSE MKT:MDGN) today announced the pricing of 6,155,000 shares of its common stock in a previously announced underwritten public offering at a price to the public of $6.50 per share. In connection with the offering, Medgenics has also granted the underwriters a 30-day option to purchase up to an additional 923,250 shares of its common stock. Gross proceeds to Medgenics from the sale of shares are expected to be approximately $40 million, excluding any exercise of the underwriters' option to purchase additional shares of common stock. If the underwriters' option is exercised in full, gross proceeds will be approximately $46 million. The offering is expected to close on or about October 6, 2015 subject to customary closing conditions.

Medgenics is a medical technology and therapeutics company developing a platform technology for orphan and rare diseases therapeutics market. Co.'s Biopump Platform Technology is designed to provide sustained protein/peptide therapy to treat a range of chronic diseases and conditions. Co. develops a device called the DermaVac to facilitate removal of micro-organs and implantation of Biopumps. Co. produces Biopumps which have demonstrated the capability for sustained production of therapeutic proteins, including erythropoietin to treat anemia (EPODURE), interferon-alpha (INF-a) to treat various forms of hepatitis (INFRADURE) and Factor VIII clotting protein to treat hemophilia (HEMODURE).
Open the MDGN Page at The Online Investor »

Company Name:  Medgenics Inc
Sector:  Biotechnology
Number of ETFs Holding MDGN:  10
Total Market Value Held by ETFs:  $3.02M
Total Market Capitalization:  $195.00M
% of Market Cap. Held by ETFs:  1.55%

Open the MDGN Page at The Online Investor (in a new window) »

October 4, 2015    5:14 PM Eastern
Quotes delayed 20 minutes

Strong Buy (4.00 out of 4)
86th percentile
(ranked higher than approx. 86% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | | Copyright © 1998 - 2015, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.